Adam Logal - Opko Health CFO
| OPK Stock | USD 1.86 0.07 3.91% |
CFO
Mr. Adam E. Logal serves as Senior Vice President, Chief Financial Officer of the Company. Mr. Logal has served as OPKOs Senior Vice President and Chief Financial Officer since March 2014, Vice President of Finance, Chief Accounting Officer and Treasurer from July 2012 until March 2014, and Director of Finance, Chief Accounting Officer and Treasurer from March 2007 until July 2012. He currently serves as chairman of the board of directors of Xenetics Biosciences, Inc., a clinicalstage biopharmaceutical company focused on discovery, research and development of nextgeneration biologic drugs and novel orphan oncology therapeutics. He previously served on the board of directors of VBI Vaccines, Inc. until 2018. From 2002 to 2007, Mr. Logal served in senior management of Nabi Biopharmaceuticals, a publicly traded, biopharmaceutical company engaged in the development and commercialization of proprietary products. Mr. Logal held various positions of increasing responsibility at Nabi Biopharmaceuticals, last serving as Senior Director of Accounting and Reporting. since 2014.
| Age | 47 |
| Tenure | 11 years |
| Address | 4400 Biscayne Boulevard, Miami, FL, United States, 33137 |
| Phone | (305) 575-4100 |
| Web | https://www.opko.com |
Adam Logal Latest Insider Activity
Tracking and analyzing the buying and selling activities of Adam Logal against Opko Health stock is an integral part of due diligence when investing in Opko Health. Adam Logal insider activity provides valuable insight into whether Opko Health is net buyers or sellers over its current business cycle. Note, Opko Health insiders must abide by specific rules, including filing SEC forms every time they buy or sell Opko Health'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Adam Logal over six months ago Acquisition by Adam Logal of 437500 shares of Opko Health subject to Rule 16b-3 | ||
Adam Logal over a year ago Acquisition by Adam Logal of 6250 shares of Xenetic Biosciences at 2.95 subject to Rule 16b-3 | ||
Adam Logal over a year ago Acquisition by Adam Logal of 6250 shares of Xenetic Biosciences subject to Rule 16b-3 |
Opko Health Management Efficiency
The company has Return on Asset of (0.0812) % which means that on every $100 spent on assets, it lost $0.0812. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (0.0386) %, meaning that it generated no profit with money invested by stockholders. Opko Health's management efficiency ratios could be used to measure how well Opko Health manages its routine affairs as well as how well it operates its assets and liabilities. The value of Return On Tangible Assets is estimated to slide to -0.05. The value of Return On Capital Employed is expected to slide to -0.08. At this time, Opko Health's Liabilities And Stockholders Equity is quite stable compared to the past year. Non Current Liabilities Total is expected to rise to about 673.8 M this year, although the value of Total Current Liabilities will most likely fall to about 107.5 M.Similar Executives
| Found 6 records | CFO Age | ||
| Frank Stokes | Castle Biosciences | 54 | |
| Andrew Emerson | IDEXX Laboratories | N/A | |
| Robert CMA | Agilent Technologies | 56 | |
| Abhishek Jain | Caredx Inc | 49 | |
| Brian McKeon | IDEXX Laboratories | 63 | |
| Robin Cowie | Biodesix | 45 | |
Management Performance
| Return On Equity | -0.0386 | ||||
| Return On Asset | -0.0812 |
Opko Health Leadership Team
Elected by the shareholders, the Opko Health's board of directors comprises two types of representatives: Opko Health inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Opko. The board's role is to monitor Opko Health's management team and ensure that shareholders' interests are well served. Opko Health's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Opko Health's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Arie Gutman, Pres API | ||
| Dr MBA, Vice Officer | ||
| FACP FASN, Senior Renal | ||
| Adam Logal, CFO, Chief Accounting Officer, Sr. VP and Treasurer | ||
| David Okrongly, President Diagnostics | ||
| Antonio Cruz, President Therapeutics | ||
| Elias MD, President Chairman | ||
| JD Esq, Chief Laboratories | ||
| Charles Bishop, Chief Renal | ||
| Hans Berner, President Iberoamerica | ||
| James DeMarco, VP Sales | ||
| Giovanni MD, Chief Officer | ||
| Phillip Frost, Chairman of the Board, CEO | ||
| Akhtar Ashfaq, Senior Vice President - Clinical Research and Development of OPKO Health's Renal Division | ||
| MBA MBA, Vice Officer | ||
| Jon MD, Advisor |
Opko Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Opko Health a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.0386 | ||||
| Return On Asset | -0.0812 | ||||
| Profit Margin | (0.07) % | ||||
| Operating Margin | (0.18) % | ||||
| Current Valuation | 1.27 B | ||||
| Shares Outstanding | 671.55 M | ||||
| Shares Owned By Insiders | 59.25 % | ||||
| Shares Owned By Institutions | 29.90 % | ||||
| Number Of Shares Shorted | 88.63 M | ||||
| Price To Earning | 7.46 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Opko Health. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. For more information on how to buy Opko Stock please use our How to buy in Opko Stock guide.You can also try the Bond Analysis module to evaluate and analyze corporate bonds as a potential investment for your portfolios..
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Opko Health. If investors know Opko will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Opko Health listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.191 | Earnings Share (0.08) | Revenue Per Share | Quarterly Revenue Growth 0.01 | Return On Assets |
The market value of Opko Health is measured differently than its book value, which is the value of Opko that is recorded on the company's balance sheet. Investors also form their own opinion of Opko Health's value that differs from its market value or its book value, called intrinsic value, which is Opko Health's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Opko Health's market value can be influenced by many factors that don't directly affect Opko Health's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Opko Health's value and its price as these two are different measures arrived at by different means. Investors typically determine if Opko Health is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Opko Health's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.